Kanserde Hedefe Yönelik Tedavi: PI3K/Akt/mTOR İnhibitörleri

Cancers generally contain multiple genetic and epigenetic abnormalities, but several key genes maintain the malignant phenotype and cellular survival. The PI3K/Akt/mTOR pathway is a central signaling system that plays a role in many important physiological events. Since the PI3K/Akt/mTOR pathway is used by many tumor types, it is thought that inhibitors used against this pathway may have a wide therapeutic efficacy. Significant response rates could not be obtained in phase 1 studies with any of the agents in monotherapy, and other options are being investigated by administering high doses in short periods and combining drugs that may affect different pathways.